GlassScriptPhysician profile
Michael Y Seiba
NPI 1750390977
$1,024.75
in general payments reported to CMS, 2019-2025
17 companies · $66.80 in 2025
The $66.80 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2020: $43.10 · 2021: $84.98 · 2022: $373 · 2023: $171 · 2024: $97.95 · 2025: $66.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $330 · Education: $5.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $330.26 |
| Education | $5.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $202.29 | 2021-2022 | |
| Convatec INC. | $165.84 | 2023-2025 | |
| Astellas Pharma US INC | $128.67 | 2020-2022 | |
| Janssen Biotech, INC. | $96.51 | 2019-2022 | |
| Axonics, INC. | $77.55 | 2022-2023 | Bulkamid |
| Boston Scientific Corporation | $53.56 | 2023 | Rezum Generator |
| Medtronic USA, INC. | $45.26 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $34.08 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.11 | 2019 | |
| Tolmar, INC. | $31.97 | 2023-2025 | Jatenzo, Eligard |
| Sumitomo Pharma America, INC. | $31.81 | 2023 | Gemtesa |
| Travere Therapeutics, INC. | $23.15 | 2019-2025 | Thiola |
| Amag Pharmaceuticals, INC. | $22.80 | 2019 | |
| Hollister Incorporated | $21.93 | 2022 | |
| Myriad Genetic Laboratories, INC. | $20.92 | 2024 | Prolaris |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $19.13 | 2019 | |
| Pfizer INC. | $17.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Seiba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.